Phase II study of amrubicin monotherapy for treating elderly and poor-risk patients with small-cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2016
Price : $35 *
At a glance
- Drugs Amrubicin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 27 Jun 2016 Status changed from recruiting to completed.
- 06 Jul 2013 New trial record